Motivated by GILT

Replacing its internal Pompe's disease program with ZC-701 from ZyStor Therapeutics Inc. will enable BioMarin Pharmaceutical Inc. to shave two years off development, free up internal manufacturing capacity, and put the company in a stronger IP position with a product that it thinks could be more efficacious than Genzyme Corp.'s Myozyme alglucosidase alfa.

But the cherry on the cake, and an important reason BioMarin acquired ZyStor this month, was to get access to ZyStor's Glycosylation Independent Lysosomal Targeting (GILT) technology for manufacturing enzyme replacement therapies...